Guardant Health, a Redwood City, CA-based developer of non-invasive cancer genomic sequencing test, completed a first closing on the majority of a $100m Series D round.
The financing round, which adds to the nearly $100 million already raised and includes equity financing and a term loan facility, is being led by OrbiMed with participation from existing investors Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Pejman Mar, Formation 8, Heritage Group, and others.
The company intends to use the funds to expand the technical and commercial lead of its Guardant360® and to further expand its Digital Sequencing™ platform into new product lines.
Led by Helmy Eltoukhy, CEO, Guardant Health develops Guardant360®, a CLIA/CAP-certified comprehensive next generation sequencing-based liquid biopsy test which enables physicians to identify genomic alterations in patients with advanced cancers, without the cost, risk, or pain of invasive biopsies.
The 70-gene blood test is used in advanced cancer patients with visceral solid tumor cancers or metastases, and interrogates all four types of genomic alterations.